Comparison of dose standard units for drug utilisation studies

被引:100
作者
Merlo, J
Wessling, A
Melander, A
机构
[1] NATL CORP PHARM, STOCKHOLM, SWEDEN
[2] NEPI FDN, MALMO, SWEDEN
[3] NEPI FDN, STOCKHOLM, SWEDEN
关键词
defined daily dose; minimum marketed dose; pharmacoepidemiology; equipotential dose; average daily dose; prescribed daily dose;
D O I
10.1007/s002280050064
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective. As employment of different dose standards would be impractical and confusing, the aim of this article is to compare the defined daily dose (DDD) with some more recently proposed standards, namely, the minimum marketed dose (MMD), the equipotential dose (ED), the average daily dose (ADD), and the non-standard prescribed daily dose (PDD). Methods. Literature review, critical comparative analysis. Results. The DDD, defined by an independent scientific committee assisting the WHO Collaborating Centre for Drugs Statistics Methodology, has been employed in a large number of national and international comparative studies at the population level, usually as number of DDDs per 1000 inhabitants per day. However, the DDD can also be used at the individual level. The PDD, not being a standard unit, can be appropriately used in a second step to explain differences detected by the DDD methodology. Conclusions. A globally accepted dose standard unit is important in drug utilisation studies, particularly if different investigations are to be compared. None of the alternatives seemed to offer any advantage over the DDD. Hence there is reason to advocate use of the DDD as the sole standard dose unit in all pharmacoepidemiologic studies.
引用
收藏
页码:27 / 30
页数:4
相关论文
共 33 条
[2]   MEASUREMENT OF DRUG CONSUMPTION - DRUGS FOR DIABETES IN NORTHERN-IRELAND, NORWAY AND SWEDEN [J].
BERGMAN, U ;
ELMES, P ;
HALSE, M ;
HALVORSEN, T ;
HOOD, H ;
LUNDE, PKM ;
SJOQVIST, F ;
WADE, OL ;
WESTERHOLM, B .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1975, 8 (02) :83-89
[3]  
BERGMAN U, 1978, DRUG UTILISATION STU
[4]   PROFILES OF ANTIBACTERIAL DRUG-USE IN AUSTRALIA AND TRENDS FROM 1987 TO 1989 - A REPORT FROM THE DRUG UTILIZATION SUBCOMMITTEE OF THE PHARMACEUTICAL-BENEFITS-ADVISORY-COMMITTEE [J].
BIRKETT, DJ ;
MITCHELL, AS ;
GODECK, A ;
GRIGSON, T ;
CULLY, R ;
LEE, C .
MEDICAL JOURNAL OF AUSTRALIA, 1991, 155 (06) :410-415
[5]  
BUSTO U, 1989, CAN MED ASSOC J, V141, P917
[6]  
Capella D, 1993, WHO Reg Publ Eur Ser, V45, P55
[7]   UTILIZATION OF ANTIHYPERTENSIVE DRUGS IN CERTAIN EUROPEAN-COUNTRIES [J].
CAPELLA, D ;
PORTA, M ;
LAPORTE, JR .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 25 (04) :431-435
[8]  
CHRISTIANSEN T, 1987, 61987 OD U DEP HLTH
[9]  
COHEN R, 1990, DIABETES METAB, V16, P59
[10]  
EKEDAHL A, 1995, EUR J CLIN PHARMACOL, V47, P381